Merrimack Pharmaceuticals, Inc.

Silver Creek Pharmaceuticals, Inc.

Torque Therapeutics, Inc.

Unikum Therapeutics Aps

Ulrik Bjerl Nielsen

Birgit Schoeberl

Michael Feldhaus

Matthew D Onsum

Brian Harms

Thomas Joseph Wickham

Bryan Linggi

Byron DeLaBarre

Raghida Bukhalid

Eric Krauland

Shaun M Lippow

Neeraj Kohli

Jeffrey David Kearns

Alexey Alexandrovich Lugovskoy

Arumugam Muruganandam

David Buckler

Anne Richard

Douglas Scott Jones

Thomas Lars Andresen

Anne King

Jonathan Basil Fitzgerald

William Kubasek

Shannon Werner

Francis David Gibbons

De-Kuan Chang

Jesse Lyons

Jonathan D Nardozzi

Ferdinando Pucci

James Andrew Rakestraw

Martin Roelsgaard Jakobsen

Byron Delabarre

Thomas Wickham

Rasmus Otkjær Bak

Anders Laustsen

Matthew David Onsum

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.

Bi-specific fusion proteins

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.

The present disclosure features, at least in part, methods for conserving cell function, e.g., immune cell function, e.g., after one or more cycles of freezing and/or thawing the nucleated cell. In embodiments, the methods comprise contacting an immune cell with a protein nanoparticle comprising an IL-15 complex.

Methods and compositions for promoting immune cell function

Immunostimulatory fusion molecules that include an immune cell targeting moiety and a cytokine molecule, pharmaceutical and formulations thereof, and methods of using and making the same, are disclosed.

T cells surface-loaded with immunostimulatory fusion molecules and uses thereof

Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.

Antibodies against epidermal growth factor receptor (EGFR) and uses thereof

Method of treating myocardial infarction by administering a bi-specific fusion protein

The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3.

Antibodies against the ectodomain of ERBB3 and uses thereof

Growing community of inventors

Quincy, MA, United States of America

Ulrik Bjerl Nielsen